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related to excessive mucus production, symptoms related 
excessive gas production gas and symptoms related excessive 
blood production. A modern scoring system should have two 
or more atomized symptoms related to each of the six 
illnesses and appropriate response scales for frequency, 
intensity and duration. 
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Anorectal toxicity is a relevant side effect of pelvic 
radiotherapy for rectal, anal, gynaecologic and prostate 
cancer. Toxicity can be scored objectively by the physician 
according to established systems such as the CTCAE 
classification. In recent years, patient-reported outcomes 
(PROs) have received increasing attention when evaluating 
acute toxicity as well as late effects of cancer treatment. 
These include information directly obtained from the patient 
on symptoms and impairment as well as on quality of life. 
This presentation will focus on validated instruments to 
measure PROs related to anorectal function, including 
quality-of-life questionnaires and organ modules, e. g. those 
developed by the EORTC Quality of Life Group, and symptom 
questionnaires e. g. to measure continence. Objective 
measurements to quantify anorectal function such as 
sphincter manometry and endoscopic scores will be 
reviewed. The relationship between PROs and objective 
function assessment with physician-rated toxicity will be 
addressed. The outcomes for the above endpoints in major 
trials of pelvic radiotherapy will be presented, with a focus 
on rectal cancer and the effects of treatment concepts 
including short-course radiotherapy and long-course 
chemoradiation. Finally, dose-volume constraints in pelvic 
radiotherapy treatment planning and potential effects of 
highly conformal techniques such as IMRT or VMAT on 
anorectal symptoms, function and quality of life will be 
examined. 
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Radiotherapy is a well recognozed curative treatment option 
for localized prostate cancer. Optimal tumor control rates 
can only be achieved with high local doses, associated with a 
considerable risk of rectal toxicity - regarded as dose-limiting 
toxicity. Apart from already widely adapted technical 
advances, as intensity-modulated radiation therapy and 
image-guided radiotherapy techniques, the application of 
spacers placed between the prostate and anterior rectal wall 
has been increasingly used in the last years.  
Biodegradable spacers, including hydrogel, hyaluronic acid, 
collagen or an implantable balloon can create the desired 
effect. They can be injected or inserted in a short procedure 
under transrectal ultrasound guidance via a transperineal 
approach. A distance of about 1.0-1.5cm is usually achieved 
between the prostate and rectum, excluding the rectal wall 
from the high isodoses. Several studies have shown well 
tolerated injection procedures and treatments. Apart from 
considerable reduction of rectal dose compared to 
radiotherapy without a spacer, clinical toxiciyt results are 
favourable. A prospective randomized trial demonstrated a 
reduction of rectal toxicity after hydrogel injection in men 
undergoing prostate image-guided intensity-modulated 
radiation therapy. The results are encouraging for continuing 
evaluation in dose escalation, hypofractionation, stereotactic 
radiotherapy or re-irradiation trials in the future. 
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Treatment planning systems (TPSs) are of high importance in 
modern brachytherapy. The users rely on the output of these 
special software; wrong calculations may result in severe 
patient harm. Thus it is necessary to systematically check 
these software programs. 
Many checks in TPSs are identical for high-dose-rate 
brachytherapy with afterloaders and low-dose-rate 
brachytherapy with seeds. But some differences exist, e.g. as 
checking of afterloader parameters.  
After the installation of the software the acceptance test is 
to be carried out. This test protocol is typically provided by 
the vendor and should be passed before further checking. In 
a second step the commissioning is carried out. In this 
procedure all clinical relevant data and properties of the TPS 
must be tested and reported. Examples for items to check 
are:  
- Afterloader characteristics (number of channels, min./max. 
channel lengths, max. allowed dwell time, …) 
- Source characteristics (nuclide, decay, …) 
- TG-43 consensus dataFor Model-based dose calculation 
algorithms, commissioning following TG-186 report 
- Applicator checks 
To ensure the consistency and data integrity of the TPS 
periodical tests should be performed after the 
commissioning. Important points are to validate the integrity 
of base parameters of the TG-43 data and the recalculation 
of patient treatment plans.  
Most TPSs offer inverse planning algorithms. The algorithm 
itself is often not fully transparent by the user, thus 
comparison with manual calculations is not practical. 
Nevertheless, the consistency of such planning technique can 
be checked by recalculation of a test plan using a constant 
parameter set. In addition to the tests above end-to-end 
tests can be performed to check the whole treatment chain, 
including imaging, TPS, afterloader, and data transfer. 
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In the past decade 3D image guided brachytherapy has been 
introduced into clinical practice worldwide. This enables 
conformation of the dose distribution to the target volume 
and avoidance of high dose to organs at risk (OAR) using CT, 
MR, and/or ultrasound (US) imaging. In such modern 
techniques sectional images give the relationship of the 
shape and the position of the applicator(s)/sources in 
relation to the anatomy of the patients. This means that the 
quality assurance (QA) programs also should include specific 
topics related to image quality additional to traditional 
procedures checking the source strengths and dose 
calculation issues. QA for image quality is well established in 
the area diagnostic and many of these procedures can be 
used also for brachytherapy. However, the procedures should 
be modified in order to reflect the conditions of use in 
brachytherapy compared to a diagnostic session.  
To optimise the image quality in diagnostic procedures 
dedicated phantom is often used. Various image quality 
parameters are tested by evaluation for example slice 
thickness, spatial resolution, uniformity and noise. In 
contrast to diagnostic imaging, the ability to reconstruct 
several points or a geometric structure with high accuracy is 
crucial in brachytherapy. Therefore, a procedure to check 
the geometric accuracy have to be included in a QA program. 
